MDI Models
Model | Origin | Creation | Efficacy* | RNAseq | Info sheet |
---|---|---|---|---|---|
JA-2042 | sarcoma | carcinogen | yes | yes | Data sheet |
JA-0009 | adenocarc. | spontaneous | yes | yes | Data sheet |
JA-0017 | adenocarc. | spontaneous | ongoing | ongoing | Data sheet |
JA-2011 | sarcoma | carcinogen | yes | yes | Data sheet |
JA-2019 | sarcoma | carcinogen | yes | ongoing | Data sheet |
JA-2041 | sarcoma | carcinogen | yes | ongoing | Data sheet |
Characteristics of MDI Models
Model | anti-PD1 | anti-CTLA-4 | Combination | therapeutic window | relevant immune cells |
---|---|---|---|---|---|
JA-0009 | low | low | low | 2 weeks | M2 macrophages |
JA-0017 | nd | nd | nd | >6 weeks | nd |
JA-2011 | low | low | nd | 2 weeks | neutrophils |
JA-2019 | high | high | nd | 2 weeks | MDSCs/Tcells |
JA-2041 | moderate | moderate | nd | 3 weeks | MDSCs/Tcells |
JA-2042 | moderate | moderate | high | 2 weeks | Treg cells |